Population pharmacokinetics of lamotrigine in Indian epileptic patients

European Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2013, Pages 43-52

  Mallaysamy, Surulivelrajan ^c   Johnson, Martin G ^a   Rao, Padma G M ^b   Rajakannan, Thiyagu ^c   Bathala, Lokesh ^d   Arumugam, Karthik ^e   Van Hasselt, Johan G C ^f   Ramakrishna, Devarakonda ^g  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b RAK MEDICAL AND HEALTH SCIENCES UNIVERSITY   (United Arab Emirates)

^c MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^d NARAYANA MEDICAL COLLEGE   (India)

^e Advinus Therapeutics Private Limited Bangalore   (India)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g Clinical Pharmacology and Pharmacokinetics   (United States)

Author keywords

Clinical study; Indian patients; Lamotrigine; Modeling and simulation; Population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID;

ACCURACY; ADULT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CAUCASIAN; COMPARTMENT MODEL; COMPUTER MODEL; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; EPILEPSY; FEMALE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MAXIMUM PLASMA CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE;

ADOLESCENT; ADULT; ANTICONVULSANTS; BODY WEIGHT; EPILEPSY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TRIAZINES; YOUNG ADULT;

EID: 84872309472     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1311-9     Document Type: Article

References (27)

1. Pellock JM (1997) Overview of lamotrigine and the new antiepileptic drugs: the challenge. J Child Neurol 12(1):S48-S52
2. Leach M, Marden C, Miller A (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug II: neuronal studies on the mechanism of action. Epilepsia 27:490-497
3. Cheung H, Kamp D, Harris E (1992) An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 13:107-112
4. Avoli M (1997) Molecular mechanisms of antiepileptic drugs. Sci Am Sci Med 7(4):54-63
5. Lamictal Product Monograph. GlaxoSmithKline.RL-2370.2011. http://us.gsk.com/products/assets/us-lamictal.pdf. Accessed 1 December 2011
6. Sharma C, Dubey R, Kumar H, Saha N (2005) Food reduces the bioavailability of lamotrigine. Ind J Med Res 121:659-664
7. Sinz MW, Remmel RP (1991) Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos 19(1):149-153
8. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554-563
9. Svein IJ, Cecilie JL (2010) Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 8:254-267
10. Cecilie JL, Philip NP (2010) Drug interactions involving second and third generation antiepileptic drugs. Expert Rev Neurother 10(1):119-140
11. David AB, Richard B, Stanley RR, Lawrence JH (2005) Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 62:1432-1436
12. Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47(121):752-760
13. Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Domínguez-Gil MA, García MJ (2008) Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483-489
14. Punyawudho B, Ramsay ER, Macias FM, Rowan JA, Collins JF, Brundage RC, Birbaum AK (2008) Population pharmacokinetics of lamotrigine in the elderly. J Clin Pharmacol 48:455-463
15. Chan V, Morris RG, Ilett KF, Tett SE (2001) Population pharmacokinetics of lamotrigine. Ther Drug Monit 23(6):630-635
16. Zhang S, Wang L, Lu W (2008) Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. Zhongguo Dang DaiEr Ke Za Zhi 10(2):105-109
17. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39:373-384
18. Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457-465
19. Sridharan R, Murthy BN (1999) Prevalence and pattern of epilepsy in India. Epilepsia 40(5):631-636
20. Johannessen SI, Battino D, Berry DJ et al (2003) Therapeutic drug monitoring of newer anti-epileptic drugs. Ther Drug Monit 25:347
21. Mallayasamy S, Arumugam K, Jain T, Rajakannan T, Bhat K, Rao PGM, Devarakonda R (2010) A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma - saliva correlation in epileptic patients. Arzneimittelforschung 60(10):599-606
22. Messenheimer JA, Mullens EL, Giorgi L (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18:281-296
23. Duffull S, Waterhouse T, Eccleston J (2005) Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 32:441-457
24. Aarons L, Ogungbenro K (2010) Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol 106(3):250-255
25. Holford N, Ma SC, Ploeger BA (2010) Clinical trial simulation: a review. Clin Pharmacol Ther 88(2):166-182
26. Fitton A, Goa K (1995) Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691-713
27. Raymond GM, Andrew BB, Anne LH, Andrew BB, Bennedetta CS (1998) Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46:547-551